Sol-Gel Technologies (SLGL) Total Liabilities (2016 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly Total Liabilities of $7.1 million for Q1 2026, up 3.67% year-over-year from $6.9 million in Q1 2025, and up 0.53% quarter-over-quarter from $7.1 million in Q4 2025.
Sol-Gel Technologies (SLGL) Total Liabilities (2016 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Total Liabilities for 11 consecutive years, with $7.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 3.67% year-over-year to $7.1 million; the TTM figure through Mar 2026 stood at $7.1 million (up 3.67% YoY), while the FY2025 annual figure was $7.1 million, up 1.57% from the prior year.
- Total Liabilities climbed to $7.1 million in Q1 2026 per SLGL's latest filing, from $7.1 million in the prior quarter.
- Across five years, Total Liabilities topped out at $8.6 million in Q3 2025 and bottomed at $3.8 million in Q3 2022.
- Historically, Total Liabilities has averaged $6.5 million across 5 years, with a median of $6.9 million in 2025.
- Annual changes were most pronounced in 2022 — Total Liabilities plunged 67.52% — and 2023, when it jumped 76.61%.
- Sol-Gel Technologies' Total Liabilities stood at $4.4 million in 2022, then surged by 50.46% to $6.6 million in 2023, then advanced by 5.31% to $7.0 million in 2024, then advanced by 1.57% to $7.1 million in 2025, then grew by 0.53% to $7.1 million in 2026.
- Business Quant data shows SLGL's Total Liabilities at $7.1 million in Q1 2026, $7.1 million in Q4 2025, and $8.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Sol-Gel Technologies | 240.26 Mn | 230.12 Mn | - | 7.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.14 Mn |
| Dec 31, 2025 | 7.11 Mn |
| Sep 30, 2025 | 8.56 Mn |
| Jun 30, 2025 | 7.43 Mn |
| Mar 31, 2025 | 6.89 Mn |
| Dec 31, 2024 | 7.00 Mn |
| Sep 30, 2024 | 8.28 Mn |
| Jun 30, 2024 | 7.10 Mn |
| Mar 31, 2024 | 7.26 Mn |
| Dec 31, 2023 | 6.64 Mn |
| Sep 30, 2023 | 6.74 Mn |
| Jun 30, 2023 | 6.81 Mn |
| Mar 31, 2023 | 4.98 Mn |
| Dec 31, 2022 | 4.42 Mn |
| Sep 30, 2022 | 3.81 Mn |
| Jun 30, 2022 | 4.63 Mn |
| Mar 31, 2022 | 5.93 Mn |
| Dec 31, 2021 | 13.60 Mn |
| Sep 30, 2021 | 11.38 Mn |
| Jun 30, 2021 | 7.16 Mn |